Ascimib 40 mg Tablet (Asciminib)

Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+ CML).

Helps control the growth and spread of leukemia cells.

Provides targeted inhibition of abnormal cancer-causing proteins.

Supports long-term disease management in eligible patients.

Used under the supervision of qualified oncology specialists.

Active Ingredient:

• Asciminib

Strength:

• Each film-coated tablet contains Asciminib equivalent to 40 mg.

Pharmaceutical Form:

• Oral film-coated tablet.

Composition Information:

This medicine contains Asciminib as the active pharmaceutical ingredient. Additional inactive ingredients may be included to ensure tablet stability, effectiveness, and quality. For a complete list of excipients, consult the product packaging or healthcare provider.

Dosage should be determined by a qualified healthcare professional based on the patient's medical condition, treatment history, and response to therapy.

Administration Guidelines:

• Take the medicine exactly as prescribed by your physician.

• Swallow the tablet whole with water.

• Do not crush, chew, or break the tablet unless advised by a healthcare professional.

• Take doses at the same time each day to maintain consistent therapeutic levels.

• If a dose is missed, follow your doctor's instructions or refer to the patient information leaflet.

• Do not discontinue treatment without medical advice.

Regular monitoring and follow-up assessments may be required during treatment to evaluate effectiveness and safety.